晚期非小细胞肺癌患者应用吉非替尼联合吉西他滨和顺铂化疗方案对NSE、CYFRA21-1水平的影响

Effects of Gefitinib Combined with Gemcitabine and Cisplatin on NSE and cyfrA21-1 Levels in Patients with Advanced NSCLC

目的:分析晚期非小细胞肺癌患者行吉非替尼联合吉西他滨和顺铂化疗治疗的有效价值。方法:选取某院于2014年3月~2019年3月期间接收的晚期非小细胞肺癌患者212例,采用随机数字表法的形式均分为研究组和对照组各106例,对照组行吉西他滨和顺铂治疗,研究组在此基础上加行吉非替尼,记录两组治疗前后的肿瘤标志物水平、总有效率以及不良反应发生率。结果:干预前,对照组和研究组血清NSE(ng/ml)、CYFRA21-1(ng/ml)、CA199(U/ml)水平对比无差异性(P>0.05);治疗后,研究组血清NSE、CYFRA21-1水平低于对照组,两组血清CA199水平对比无差异性(P>0.05);研究组化疗60日后总有效率(73.58%)高于对照组(47.17%),组间对比具有统计学意义(P<0.05)。结论:吉非替尼联合吉西他滨和顺铂化疗治疗非小细胞肺癌效果较佳,其中血清NSE能够作为晚期非小细胞肺癌化疗的有效评定指标。

Objective:To analyze the effective value of gefitinib combined with gemcitabine and cisplatin in patients with advanced non-small cell lung cancer.Methods:212 cases of advanced non-small cell lung cancer patients in a hospital from March 2014 to March 2019 were selected and divided into the study group and the control group by random digital table method,with 106 cases in each group.The control group was given gemcitabine and cisplatin therapy,and the study group was given giefitinib on the basis of the control group,then the tumor markers levels,total efficiency,and the incidence of adverse reactions before and after treatment in the two groups were recorded.Results:Before the intervention,there was no difference in serum NSE(ng/ml),CYFRA21-1(ng/ml),and CA199(U/ml)levels between the two groups(P>0.05).After treatment,the serum NSE and the CYFRA21-1 level in the study group were lower than those in the control group,and there was no difference in serum CA199 levels between the two groups(P>0.05).The total efficiency in the study group(73.58%)was higher than 47.17%in the control group after 60d of chemotherapy,and the difference between the two groups was statistically significant(P<0.05).Conclusion:Gefitinib combined with gemcitabine and cisplatin is effective in the treatment of non-small cell lung cancer,and serum NSE can be used as an effective evaluation indicator for advanced non-small cell lung cancer chemotherapy.